Vitamin C can save the lives of those badly infected with COVID-19 and make symptoms of milder infections less severe.
This is a key finding from a major review by senior experts from around the world on the effects of vitamin C on the virus.
Other findings include:
- Many severely infected patients have such low vitamin C levels they are suffering from scurvy
- A controlled trial found high dose vitamin C more effective than a steroid
- The vitamin C level of patients in intensive care predicts their chances of survival
- Humans are one of the few animals that cannot make vitamin C.
Results from more than 100 studies, included a gold-standard RCT (Randomised Controlled Trial) which showed that Vitamin C could cut the death rate of patients in intensive care units by 68%. The patients got vitamin C or sterile water from a drip.
A similar trial comparing a steroid drug (dexamethasone) with a placebo in June was hailed as a success. It reduced deaths by just 3%.
The amount of vitamin C needed to the reduce deaths and time on ventilators in ICUs ranged between 6 and 24 grams a day, says lead author and nutritionist Patrick Holford.
Another author, Dr Anitra Carr, explained why such high doses are needed. ‘When you get a severe infection, your body uses up vitamin C at a much faster rate in order to support the immune system.
‘That’s because humans are one of the few animals that can’t make vitamin C, so we can’t increase supplies when needed.’ Dr Carr, who is associate professor at the University of Otago in New Zealand, points out that only animals that don’t make vitamin C – primates, guinea pigs and bats – are susceptible to COVID-19.
Further support for using high doses come from studies showing that most COVID-19 patients coming into ICUs already have very low vitamin C levels.
‘Their levels are often undetectable’ says co-author Professor Paul Marik, Chief of Critical Care Medicine at Eastern Virginia Medical School. ‘That’s what you see in patients with scurvy. This infection induces scurvy. We can predict how likely patients are to survive by their level of vitamin C’
Marik explains that to stop scurvy you need high doses of vitamin C. It is also vital for damping down the dangerous inflammation that develops as COVID-19 progresses and can be fatal.
By combining vitamin C with steroids and anticoagulant drugs Professor Marik and others have reduced the death rate of critical ill COVID-19 patients to less than 5%. “No-one is dying who doesn’t have both a pre-existing end stage disease and is over 85 years old,” he says.
Another author on the paper, which is published in Nutrients is David Smith, Emeritus Professor of pharmacology at the University of Oxford who is presenting the evidence to the National Institute for Clinical Evidence (NICE).
Philip Calder from the University of Southampton, who is Professor of Nutritional Immunology within Medicine is talking about the paper to the Nutrition Society today, to inform members of the UK’s Scientific Advisory Committee of Nutrition (SACN) who advise government on policy.
The full scientific review paper, published in the journal Nutrients, is viewable in the ‘science’ section of www.vitaminC4covid.com.
Abstract: https://www.mdpi.com/2072-6643/12/12/3760
Full paper pdf: https://www.mdpi.com/2072-6643/12/12/3760/pdf
Nutrients (ISSN 2072-6643; CODEN: NUTRHU) is a peer-reviewed open access journal of human nutrition published monthly online by MDPI.
VitaminC4Covid.com is an international campaign backed by over 900 professors, doctors, nutrition professionals and other healthcare practitioners, from over 50 countries. The campaign is calling for the government and its public health and nutrition agencies to take vitamin C seriously and thoroughly assess the evidence, fund studies of vitamin C in relation to COVID-19, and for ‘vitamin C for COVID-19 or corona’ no longer being classified as false information in both digital, broadcast and print media. The full scientific review paper, published in the journal Nutrients, is viewable in the ‘science’ section of www.vitaminC4covid.com.